Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733251 | 0.98 | KEAP1 (0.57) | KEAP1NFE2L2ALDH1A1HTTALOX12 | |
| SCHEMBL2734248 | 0.98 | KEAP1 (0.57) | KEAP1NFE2L2ALDH1A1HTTALOX12 | |
| SCHEMBL2734662 | 0.98 | KEAP1 (0.57) | KEAP1NFE2L2ALDH1A1HTTALOX12 | |
| SCHEMBL14495116 | 0.87 | KEAP1 (0.51) | KEAP1NFE2L2ALDH1A1HTTALOX12 | |
| SCHEMBL8778827 | 0.84 | KEAP1 (0.60) | KEAP1NFE2L2ALDH1A1HTTALOX12 | |
| SCHEMBL7194392 | 0.82 | KEAP1 (0.57) | KEAP1NFE2L2ALDH1A1HTTALOX12 | |
| SCHEMBL9099317 | 0.82 | KEAP1 (0.59) | KEAP1NFE2L2ALDH1A1HTTRAPGEF4 | |
| SCHEMBL9102994 | 0.82 | KEAP1 (0.59) | KEAP1NFE2L2ALDH1A1HTTRAPGEF4 | |
| SCHEMBL8778811 | 0.82 | KEAP1 (0.59) | KEAP1NFE2L2ALDH1A1HTTRAPGEF4 | |
| SCHEMBL2733953 | 0.82 | KEAP1 (0.59) | KEAP1NFE2L2ALDH1A1HTTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338110-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | WISCONSIN MED COLLEGE INC (US) | 2013-12-19 | — | — | US | disclosed |
| US-8466130-B2 | Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers | COLBY PHARMACEUTICAL COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | COLBY PHARMACEUTICAL COMPANY (US) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338110-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | TFAM, HSPD1, NLN | KEAP1 982/4885NFE2L2 144/4885ALDH1A1 1738/4885 |
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | TFAM, HSPD1, NLN | KEAP1 982/4885NFE2L2 144/4885ALDH1A1 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.